INGREZZA
What it isReversible VMAT2 inhibitor that reduces presynaptic dopamine packaging; tardive dyskinesia.
Why this oneIt usually needs less titration than deutetrabenazine and lets the causative antipsychotic continue.
What limits itSomnolence and QT prolongation; CYP2D6 or CYP3A4 inhibition raises exposure.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Tardive dyskinesia | Adults | 40 mg QD | 80 mg QD (after 1 wk); 40–60 mg QD per response | 80 mg QD |
| Chorea associated with Huntington's disease | Adults | 40 mg QD | 80 mg QD (↑20 mg q2wk); 40–60 mg QD per response | 80 mg QD |
Titration Tardive dyskinesia: increase after 1 week. Huntington's chorea: increase in 20 mg increments every 2 weeks.
Renal Undefined
Hepatic Moderate or severe hepatic impairment: 40 mg QD.
Pregnancy Insufficient human data; animal data show increased stillbirths/pup mortality — may cause fetal harm.
Lactation Do not breastfeed during treatment and for 5 days after the final dose.
NO BOXED WARNINGS
Principal riskSomnolence and QT prolongation
Cost, est. cash$3,000–$10,000/month
Generic entry2038 (settlement)
Legacy pregnancy categoryNot assigned — PLLR-era drug
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.

Open Valbenazine in the interactive console ↗
